References for Part 1 of Over Dose:
The Case Against the Drug Companies
1. Wernicke, JF, Dunlop, SR, Dornseif,
BE, Bosomworth, JC, Humbert, M. Low-dose fluoxetine therapy for depression.
Psychopharmacology Bulletin, 1988; 24(1):183-188.
2. Louie, AK, Lewis, TB, Lannon, MD. Use
of low-dose fluoxetine in major depression and panic disorder. Journal
of Clinical Psychiatry, 1993;54(1):435-438.
3. Lazarou J; Pomeranz BH; Corey PN. Incidence
of adverse drug reactions in hospitalized patients: a meta?analysis of
prospective studies [see comments]. JAMA, 1998 Apr 15, 279(15):1200?5.
4. Ibid.
5. Gilman, AG, Rall, TW, Nies, AS, Taylor,
P. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New
York: Pergammon Press, 1990 and 1996.
6. Kolata, G. (New York Times News Service).
Who cares when our drugs fail? San Diego Union-Tribune, Weds., Oct. 15,
1997: E-1,5.
7. Melmon, K.L., Morrelli, H.F., Hoffman,
B.B., & Nierenberg, D.W. Melmon and Morrelli's Clinical Pharmacology:
Basic Principles in Therapeutics. (3rd Edition). New York: McGraw-Hill,
Inc., 1993.
8. Moore TJ; Psaty BM; Furberg CD. Time
to act on drug safety. JAMA, 1998 May 20, 279(19):1571?3.
9. Cullen DJ; Bates DW; Small SD; Cooper
JB; Nemeskal AR; Leape LL. The incident reporting system does not detect
adverse drug events: a problem for quality improvement. Joint Commission
Journal on Quality Improvement, 1995 Oct, 21(10):541?8.
10. Bates DW. Drugs and adverse drug reactions:
how worried should we be? JAMA, 1998 Apr 15, 279(15):1216?7.
11. Dickinson, JG. FDA seeks to double
effort on confusing drug names. Dickinson's FDA Review, March 2000; 7(3):13-14.
12. Marks L. "Not just a statistic":
the history of USA and UK policy over thrombotic disease and the oral
contraceptive pill, 1960s?1970s. Social Science and Medicine, 1999 Nov,
49(9):1139?55.
[12A. Snider, S. The Pill: 30 Years of Safety Concerns. U.S. Food and
Drug Administration, Dec. 1990; FDA Website.]
13. Van Hoften C; Burger H; Peeters PH;
Grobbee DE; Van Noord PA; Leufkens HG. Long?term oral contraceptive use
increases breast cancer risk in women over 55 years of age: the DOM cohort.
International Journal of Cancer, 2000;87(4):591?4.
14. Burke, W. Oral Contraceptives and Breast
Cancer. JAMA, Oct. 11, 2000; 284:1837-38.
15. Schlesselman JJ. Net effect of oral
contraceptive use on the risk of cancer in women in the United States.
Obstetrics and Gynecology, 1995 May, 85(5 Pt 1):793?801.
16. Bagshaw, S. The Combined Oral Contraceptive.
Drug Safety, 1995; 12:91-96.
17. Ettinger B. Personal perspective on
low?dosage estrogen therapy for postmenopausal women. Menopause, 1999;
6(3):273?6.
18. Weinstein L. Efficacy of a continuous
estrogen?progestin regimen in the menopausal patient. Obstetrics and Gynecology,
1987;69(6):929?32.
19. Greendale GA, Reboussin BA, Hogan P,
Barnabei VM, Shumaker S, Johnson S, et al. Symptom relief and side effects
of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin
Interventions Trial. Obstetrics and Gynecology, 1998;92(6):982?8.
20. Ettinger B. op cit.
21. American Society of Hospital Pharmacists.
American Hospital Formulary Service, Drug Information 1999. Gerald K.
McEvoy, Editor. Bethesda: 1999.
22. American Medical Association. AMA Drug
Evaluations, Annual 1993. Chicago: American Medical Association, 1993.
23. Lindsay R; Hart DM; Clark DM. The minimum
effective dose of estrogen for prevention of postmenopausal bone loss.
Obstetrics and Gynecology, 1984;63(6):759?63.
24. Ettinger B. A practical guide to preventing
osteoporosis. Western Journal of Medicine, 1988;149(6):691?5.
25. Schairer C; Lubin J; Troisi R; Sturgeon
S; Brinton L; Hoover R. Menopausal estrogen and estrogen?progestin replacement
therapy and breast cancer risk. Jama, 2000 Jan 26, 283(4):485?91.
26. Persson I; Weiderpass E; Bergkvist
L; Bergstrom R; Schairer C. Risks of breast and endometrial cancer after
estrogen and estrogen?progestin replacement. Cancer Causes and Control,
1999 Aug, 10(4):253?60.
27. Peck, C., Barr, W., Benet, L., Collins,
J., Desjardins, R., Furst, D., et al. Opportunities for integrating of
pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug
development. Journal of Clinical Pharmacology, 1994; 34:111-9.
28. Peck CC. Drug development: improving
the process. Food Drug Law Journal, 1997; 52:163-7.
29. Woosley, RL. Drug Labeling Revisions
-- Guaranteed to Fail? JAMA, Dec. 20, 2000; 284(23):3047-49.
30. Sussman, N. More Questions Than Answers.
Primary Psychiatry, 2000; 7:6.
31. Angell, M. The Pharmaceutical Industry
-- To Whom Is It Accountable? New England Journal of Medicine, 2000; 342:1902-4.
32. Melmon et al., op. cit.
33. Bowman, L. 51% Of U.S. Adults Take 2 Pills or More a Day, Survey Reports
(Scripps Howard News Service). San Diego Union-Tribune, Weds., Jan. 17,
2001:A8.
34. Cullen et al., op. cit.
35. Gilman et al., op. cit.
36. Cohen JS; Insel PA. The Physicians'
Desk Reference. Problems and possible improvements. Archives of Internal
Medicine, 1996; 156(13):1375?80.
37. Cohen, JS. Adverse drug effects, compliance,
and the initial doses of antihypertensive drugs recommended by the Joint
National Community vs. the Physicians' Desk Reference. Archives of Internal
Medicine, 2001;161:880-85.
38. Cohen, JS. Dose Discrepancies between
the Physicians' Desk Reference and the Medical Literature, and Their Possible
Role in the High Incidence of Dose-Related Adverse Drug Events. Archives
of Internal Medicine, April 9, 2001: Scheduled for Publication.
39. Cohen, J.S. Ways To Minimize Adverse
Drug Reactions: Individualized Doses and Common Sense Are Key. Postgraduate
Medicine, Sept. 1999; 106: 163-72.
40. Cohen, JS. Adverse Drug Reactions:
Effective Low-Dose Therapies for Older Patients. Geriatrics, Feb. 2000;
55(2):54-64.
41. Cohen, JS. Comparison of FDA Reports
of Patient Deaths Associated with Sildenafil (Viagra) and with Injectable
Alprostadil. Annals of Pharmacotherapy, March 2001;35:285-88.
42. Cohen, JS. Is the Product Information
on Sildenafil (Viagra) Adequate to Facilitate Optimal Therapeutics and
to Minimize Adverse Events? Annals of Pharmacotherapy, March 2001;35:337-42.
43. Cohen, JS. Should Patients Be Given
a Low Test Dose of Viagra Initially? Drug Safety, July 2000; 23:1-10.
44. Rennie, D. Fair Conduct and Fair Reporting
of Clinical Trials. JAMA, 1999; 282:1766-68.
45. Bodenheimer, T. Uneasy Alliance --
Clinical Investigators and the Pharmaceutical Industry. New England Journal
of Medicine, 2000; 342:1539-44.
46. Huston, P. Redundancy, Disaggregation,
and the Integrity of Medical Research. Lancet, 1996, Apr. 13;347(9007):1024-26.
47. Bodenheimer, op. cit.
48. Hotz, RL. Secrecy is often the price
of medical research funding. Los Angeles Times, May 18, 1999; A-2, 21.
49. Angell, M. Is Academic Medicine for
Sale? New England Journal of Medicine, May 18, 2000; 342:1516-18:
50. Ibid.
51. Sussman, op. cit.
52. Wazana, A. Physicians and the pharmaceutical
industry: is a gift ever just a gift? JAMA, 2000; 283(3):373?80.
53. Physicians' Desk Reference, 54th Edition.
Montvale, N.J.: Medical Economics Company, 2000.
Return to Part
1 of Over Dose: The Case Against the Drug Companies